Director, Commercial Insights and Analytics

Director, Commercial Insights and Analytics

Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. It’s an exciting time to be part of Team Olema , with our transfor mation into a fully integrated oncology company well underway , t op-line data from our lead program expected later this year , and our first potential commercial launch on the horizon.

Our lead product candidate,palazestrant, isa novel, orallyavailablecomplete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) currently intwopivotal

Phase 3clinicaltrials.

We expect top-line data from OPERA-01,our ongoing

Phase 3 trial ofpalazestrantas a monotherapy in patients with second- or third-lineER+/HER2-metastatic breast cancer (MBC), in the fallwhich, if successful, could lead to our first potential approval and commercial launchin 2027. OPERA-02,our Phase 3 trial ofpalazestrantin combination withribociblibin patients with frontlineER+/HER2- MBC, is enrolling patients.

Togetherwith its mechanism of action, pharmacokinetic properties,andthe potential todemonstrateactivity in bothESR1wild-type and mutant tumors,palazestranthas the potential to transform the metastatic breast cancer treatment paradigm andaccessa $15 billion global market opportunity.

Our follow-on product candidate, OP-3136, is a potent KAT6 inhibitor withthepotential to generate further value and meaningfullyimpactthemetastatic breastcancertreatment landscape – particularly in combination withpalazestrant.

We recently reported encouraging

Phase 1monotherapydata from this program across multiple solid tumor types andareadvancingpatientenrollment in theongoingcombinationarmsin MBC.

Aspiring to transform the metastatic treatment paradigm is an ambitious endeavor that requires aresolute approach to developing better therapies and apassionateteamdedicated tohelping the patients we serve feel better,longer.

Wepossessadeepcommitment toour shared purpose,the sustained pursuit of excellence, cultivatingthecouragerequiredto advance our programs, drive to succeed, and a collective capacity for adaptability through learning, growth, and evolution. Team Olema is made up of nimble self-starters who bring consistency in their quest for the extraordinary every single day.

Ifyou’rereadyto bepartof atenacious,courageous,agile, andgrowingteam,join us in makinga profound impact,together–
for our patients, for your career, and for what’s beyond .

About the Role>>>

Director, Insights and Analytics

Olema Oncology is seeking a
Director, Commercial Insights and Analytics
to build and lead an integrated insights capability supporting commercial strategy, launch readiness, and lifecycle planning. The role reports to the SVP, Commercial Strategy and Operations.

The Director of Insights and Analytics will serve as a strategic thought partner to Commercial leadership and cross-functional stakeholders, bringing together
primary market research, forecasting, and competitive intelligence,to address Olema’s most important business questions.

This individual will develop a deep understanding of customers, patients, and competitors, and translate that understanding into clear implications and recommendations for the business. The role willbe responsible for ensuring that Olema has the right insights at the right time to inform decisions ranging from product strategy and launch planning to customer engagement, market development, and investment prioritization.

This is a highly visible, hands-on role for a leader who is comfortable framing ambiguous business questions, designing research and analytical approaches, pressure-testing assumptions, and translating disparate…